Exit Stage Left: As Pfizer Merger Nears, Wyeth Ends its Partnership with Progenics
This article was originally published in The Pink Sheet Daily
Executive Summary
Ahead of completion of its merger with Pfizer, Wyeth essentially is paying its partner to take back the low-earning constipation drug.
You may also be interested in...
Baker Plans Business Development Focus For Progenics Pharma
The company founder stepped down as CEO to make room for a more business-minded leader.
Baker Plans Business Development Focus For Progenics Pharma
The company founder stepped down as CEO to make room for a more business-minded leader.
Progenics Finds New Partner For Relistor In Salix
A casualty of the Pfizer/Wyeth merger, Relistor rights bring Progenics $60 million upfront plus up to $290 million in milestones plus royalties.